[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Rajiv Gandhi Cancer Institute & Research Center, India\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":98},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100612839","short-course-or-long-course-radiotherapy-as-total-neoadjuvant-therapy-in-locally-advanced-rectal-cancer-100612839",false,"NCT07258797","Short Course or Long Course Radiotherapy as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer","Short Course or Long Course Radiotherapy as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer : A Prospective, Open Label, Single Institution, Randomized, Parallel Arm Comparative Study","SHOOL","Inclusion Criteria:\n\n1. Histologically confirmed adenocarcinoma of the rectum\n2. Locally advanced disease based on MRI including cT3-T4 and\u002For node positive disease (cN1 or N2)\n3. Tumor located within 15 cm from the anal verge (confirmed by endoscopy or MRI)\n4. ECOG performance status 0-2\n5. Hemoglobin ≥ 9 g\u002FdL\n6. Absolute neutrophil count ≥ 1,500\u002Fmm³\n7. Platelets ≥ 100,000\u002Fmm³\n8. Total bilirubin ≤ 1.5 × ULN\n9. Aspartate transaminase\u002FAlanine transaminase ≤ 2.5 × ULN\n10. Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 60 mL\u002Fmin\n11. Fit for neoadjuvant therapy and curative resection\n12. Willing and able to provide written, informed consent\n13. Baseline MRI and biopsy (even if done outside) must be reviewed and approved by the institutional radiology and pathology review board, requiring concurrence from two independent pathologists and two independent radiologists\n\nExclusion Criteria:\n\n1. Metastatic disease at presentation (distant nodes, liver, lung, peritoneum, etc.)\n2. Prior pelvic radiotherapy or systemic chemotherapy for rectal cancer\n3. Presence of synchronous malignancies or previous malignancy within 5 years except: Treated basal cell or squamous cell carcinoma of the skin, In situ cervical cancer, Active uncontrolled infection\n4. Known HIV infection with CD4 \\\u003C 200 cells\u002FμL, or active hepatitis B or C\n5. Severe comorbid conditions precluding therapy (e.g., decompensated cardiac, hepatic, or renal disease)\n6. Pregnant or breastfeeding women\n7. Inability to comply with protocol requirements or follow-up schedule\n8. Psychiatric illness or social situations that may limit compliance with study requirements","ALL","18 Years","75 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study compares two standard radiotherapy approaches (short-course vs. long-course) given before surgery in patients with locally advanced rectal cancer. The goal is to see which treatment is more effective and better tolerated.",[28],"Adenocarcinoma of the Rectum",[30,31,32,33,34],"SHORT COURSE RADIOTHERAPY","LONG COURSE RADIOTHERAPY","RECTAL CANCER","OUTCOMES","SURVIVAL","NOT_YET_RECRUITING","2025-11-20",{"date":38,"type":39},"2025-12-02","ACTUAL",{"date":41,"type":22},"2025-12-01",{"date":43,"type":22},"2029-03-31",{"name":45,"class":46},"Rajiv Gandhi Cancer Institute & Research Center, India","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":5},"100570836","phase-3-neoadjuvant-chemotherapy-for-locally-advanced-gall-bladder-cancer--a-randomized-control-trial-neogb-100570836","NCT06712420","Neoadjuvant Chemotherapy for Locally Advanced Gall Bladder Cancer : a Randomized Control Trial (NEOGB)","Neoadjuvant Chemotherapy Versus Upfront Surgery for Locally Advanced Resectable Gall Bladder Cancer : A Randomized Trial","NEOGB","Inclusion Criteria:\n\n* ECOG 0-2\n* Locally advanced resectable GBC defined as Clinical T3\u002F4 disease or Regional LN involvement on imaging studies.\n* Post cholecystectomy GBC with residual disease on imaging, History of bile spillage during primary surgery , history of piece-meal removal of gall bladder during simple cholecystectomy, Regional LN involvement on imaging studies.\n\nExclusion Criteria:\n\n1. Early GBC ( cT1\u002FT2) without significant lymphadenopathy or liver infiltration on radiological imaging .\n2. Locally advanced disease requiring major hepatectomy or whipple's pancreatoduodenectomy.\n3. Post cholecystectomy GBC without any evidence of spillage of residual disease on radiological imaging.\n4. Obstructive jaundice due to involvement of biliary tree by tumour.\n5. Vascular involvement such as common hepatic artery, MPV right hepatic artery or right portal vein.\n6. Any distant metastasis or isolated port site metastasis\n7. Involvement of non-regional LN (e.g . Celiac LN, SMA lymph node, inter-aortocaval or left para-ortic LN).\n8. Poor performance status ECOG 3 or more.\n9. Pregnancy.\n10. Inability or unwillingness to follow study protocol","70 Years",{"count":58,"type":22},114,[60],"PHASE3","to study role of chemotherapy treatment for gall bladder cancer before surgery as compared to surgery directly",[63],"Gall Bladder Carcinoma",[65],"gallbladder, locally advanced, neoadjuvant","RECRUITING","2025-04-13",{"date":69,"type":39},"2025-04-16",{"date":71,"type":39},"2025-01-01",{"date":73,"type":22},"2028-12",{"name":45,"class":46},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":47},"100522822","phase-2-dose-escalation-using-hypoxia-adjusted-radiotherapy-100522822","NCT06087614","Dose Escalation Using Hypoxia-adjusted Radiotherapy","A Phase II Randomised Controlled Study Assessing the Role of Dose Escalation Using [18F] FMISO PET CT in Head and Neck Cancer: The DE-HyART (Dose Escalation Using Hypoxia-adjusted Radiotherapy) Protocol","DE-HyART","Inclusion Criteria:\n\n* Age: 18 - 70 years\n* Willingness to sign informed consent (written\u002Fvideo documentation)\n* Performance status: ECOG 0 - 2\n* Histology proved - squamous cell carcinoma\n* Any grade, gender\n* Tumour sites: Oral Cavity, Oropharynx, Hypopharynx and Larynx\n* Sufficient bone marrow reserve within the last 14 days.\n\n  * Hb: \\> 10g\u002Fdl (corrected)\n  * TLC: \\> 4,000 per cumm\n  * Platelet: \\>1.5Lakh per cumm\n* Liver functions and kidney functions within normal limits\n* Nutritional and dental assessment before inclusion into the study\n\nExclusion Criteria:\n\n* HPV (p16) positive tumours\n* Prior surgery and\u002For radiation therapy given for any HNC\n* T1\u002FT2 Glottis\n* Metastatic disease or disease not amenable for definitive locoregional treatment.\n* Medical co-morbidity hampering the administration of radiation and\u002For chemotherapy (cisplatin)\n* Pregnancy or lactation",{"count":84,"type":22},124,[86],"PHASE2","DE-HyART is a phase II clinical trial aimed at understanding the effects of escalating radiation doses to hypoxic sub-volumes inherent to squamous cell head and neck cancer. The study is aimed at assessing locoregional control, feasibility, and acceptable toxicity with such a strategy.",[89],"Head and Neck Squamous Cell Carcinoma","2025-01-16",{"date":92,"type":39},"2025-01-17",{"date":94,"type":39},"2024-04-08",{"date":96,"type":22},"2028-04",{"name":45,"class":46},""]